Minerva Capital Research Solutions

Pfizer

NSE: PFIZERBSE: 500680
Compare with peers
₹ 3,728.10▲ 10.1 (+0.27%)28 Oct, 03:29 pm IST
Market cap
₹ 16,513 Cr.
P/E
107.8x
P/B
4.02x
52-week range
3,589 – 5,346
ROE
18%
ROCE
24%
Dividend yield
2%
Debt / equity
0.02
Sector
Pharmaceuticals & Biotechnology
Industry
Pharmaceuticals
Listed on
NSE, BSE

About

Pfizer Limited (Pfizer) is an India-based multinational pharmaceutical company focusing on therapy in four business categories, namely, Vaccines, Hospitals, Internal Medicine, and Inflammation and Immunology. Pfizer’s Vaccines Division focuses on Prevenar 13, a Pneumococcal Conjugate Vaccine approved for administering to individuals of all ages against pneumococcal disease, an infection caused by streptococcus pneumoniae bacteria. Internal Medicine portfolio includes approximately 17 specialties and seven therapy areas, including respiratory, multivitamin and multimineral, gastrointestinal, pain, neuroscience, cardiovascular and women’s healthcare. Pfizer Hospital Business Unit focuses on providing advanced anti-infectives to institutions such as hospitals and nursing homes. Inflammation and Immunology focuses on discovering and developing novel therapeutics for chronic autoimmune diseases. Its brands include Prevenar13, CorexDX, Dolonex, Enbrel, Becosules and Folvite, among others.

Quick check

The five things to look at first. Open one for more.

Compared with its industry

Pharmaceuticals: 221 companies →

Pfizer against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

  • Valuation (P/E)107.8 against a typical 33.2: pricier than most peers (1st = cheapest).196th of 220
  • Sales growth+8.3% against a typical +15.6% from a year earlier.119th of 197
  • Profit growth+6.3% against a typical +18.9% from a year earlier.99th of 160
  • Share price, 3 months−21.8% against a typical −1.8%.186th of 200
  • Size₹ 16,512.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).29th of 199

Board meetings

Results dates and other board meetings. Full calendar

Details
3 Nov 2026UpcomingFinancial ResultsThis is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, November 3, 2026, inter alia, to consider, approve and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.
28 Jul 2026Financial ResultsTo consider and approve the financial results for the period ended Jun 30, 2026
12 May 2026Financial Results/DividendTo consider and approve the financial results for the period ended March 31, 2026 and dividend
9 Feb 2026Financial ResultsTo consider and approve the financial results for the period ended December 31, 2025
12 Nov 2025Financial ResultsTo consider and approve the financial results for the period ended September 30, 2025
13 Aug 2025Financial ResultsThis is to inform that a meeting of the Board of Directors of the Company is scheduled to beheld on Wednesday, August 13, 2025 inter alia, to consider, approve and take on record theUnaudited Financial Results of the Company for the quarter ended June 30, 2025.
19 May 2025Financial Results/DividendThis is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Monday, May 19, 2025 inter alia, to consider, approve and take on record the Audited Financial Results of the Company for the quarter and Financial Year ended March 31, 2025 and to consider recommendation of dividend, if any, for the Financial Year ended March 31, 2025.

Share price

1Y change −29.78%
Volume (shares)Price (₹)
Close price

Financials

Consolidated figures in ₹ crore.

Quarterly results
₹ Cr.Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales575540547563589538592603642645629653
Expenses393387357385399392364393412417393406
Operating Profit183153189177189146228210230228236248
OPM %32%28%35%32%32%27%38%35%36%35%38%38%
Other Income3644754243432176742−205045
Interest337222332221
Depreciation151814151515161414141514
Profit before tax201176244203215172426260255192269277
Tax %26%26%27%26%26%26%22%26%26%26%26%26%
Net Profit149130179151158128331192189142200204
EPS in Rs32.5628.4139.132.9434.6127.8972.3441.9141.323143.6844.7

Growth and returns

Compounded yearly rates over each period.

Compounded Sales Growth
10 Years
2%
5 Years
2%
3 Years
1%
TTM
11%
Compounded Profit Growth
10 Years
10%
5 Years
9%
3 Years
8%
TTM
14%
Stock Price CAGR
10 Years
10%
5 Years
−3%
3 Years
8%
TTM
—
Return on Equity
10 Years
17%
5 Years
18%
3 Years
16%
TTM
—

Shareholding

Latest: Jun 2026.

Promoters
63.92%
0 pts in a year
FIIs
1.65%
−0.75 pts in a year
DIIs
17.8%
+0.57 pts in a year
Public
16.62%
+0.17 pts in a year

P/E and EPS over time

Daily P/E and trailing 12-month EPS. EPS updates with each result.

P/E 107.8xEPS (12 months) ₹ 51.40Median P/E 60.8x
P/E (times)EPS (₹)

Peers

Listed companies in the same business.

Peer comparison
Pfizer₹ 3,728.10₹ 16,513 Cr.107.8x4x18%—
Aurobindo Pharma₹ 1,569.30₹ 90,294 Cr.25.1x2.4x9.9%10.4%
Neuland Laboratories₹ 18,882.05₹ 24,132 Cr.64.3x12.6x21.4%18%
Unichem Laboratories₹ 470.00₹ 3,309 Cr.54.3x1.5x9.8%11.5%
Jagsonpal Pharmaceuticals₹ 213.00₹ 1,402 Cr.34.3x5.4x16.7%15%
Themis Medicare₹ 90.00₹ 826 Cr.632.2x2.5x0.3%0.3%

Management

Amit Agarwal
Chief Financial Officer, Executive Director - Finance
Meenakshi Nevatia
Managing Director, Executive Director
Sharad Goswami
Senior Director - Policy and Public Affairs
Pankaj Gupta
Senior Director - Medical Affairs
Manish Paliwal
Senior Director - Regulatory Affairs
Pazhania Pillai Rengan
Executive Director - Plant Operations
Saral Gupta
Director - Commercial Channel and Market Access
Prashant Mahalingam
Category Lead Internal Medicine & Hospitals

Prices are delayed and for information only. Nothing on this page is investment advice.